✦ LIBER ✦

Minimal residual disease in leukaemia patients

✍ Scribed by Tamasz Szczepariski; Alberto Orfão; Vincent HJ van der Valden; Jésus F San Miguel; Jacques JM van Dongen

Book ID: 117782299
Publisher: The Lancet
Year: 2001
Tongue: English
Weight: 205 KB
Volume: 2
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(00)00418-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Minimal residual disease in chronic myel

Minimal residual disease in chronic myeloid leukaemia patients

✍ Andreas Hochhaus 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Minimal residual disease predicts outcom

Minimal residual disease predicts outcome in paediatric patients with relapsed acute lymphoblastic leukaemia

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Clinical significance of minimal residua

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation

✍ Campana, Dario; Leung, Wing 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Minimal residual disease monitoring in c

Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR

✍ Raponi, Sara; Della Starza, Irene; De Propris, Maria S.; Del Giudice, Ilaria; Ma 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

Minimal residual disease studies are ben

Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia

✍ V. De Haas; L. Oosten; R. Dee; O. J. H. M. Verhagen; W. Kroes; H. Van Den Berg; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Achievement of complete molecular respon

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Ros 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cas